Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 15 de 15
Filter
Add more filters










Publication year range
1.
Sci Rep ; 11(1): 9405, 2021 04 30.
Article in English | MEDLINE | ID: mdl-33931709

ABSTRACT

Histamine receptor 2 (H2R) blockade is commonly used in patients with gastric, duodenal ulcers or gastroesophageal reflux disease. Beyond the gastrointestinal tract, H2R is expressed by multiple immune cells, yet little is known about the immunomodulatory effects of such treatment. Clinical reports have associated H2R blockade with leukopenia, neutropenia, and myelosuppression, and has been shown to provide clinical benefit in certain cancer settings. To systematically assess effects of H2R blockade on key immune parameters, a single-center, single-arm clinical study was conducted in 29 healthy subjects. Subjects received daily high dose ranitidine for 6 weeks. Peripheral blood immunophenotyping and mediator analysis were performed at baseline, 3 and 6 weeks into treatment, and 12 weeks after treatment cessation. Ranitidine was well-tolerated, and no drug related adverse events were observed. Ranitidine had no effect on number of neutrophils, basophils or eosinophils. However, ranitidine decreased numbers of B cells and IL-2Rα (CD25) expressing T cells that remained lower even after treatment cessation. Reduced serum levels of IL-2 were also observed and remained low after treatment. These observations highlight a previously unrecognised immunomodulatory sustained impact of H2R blockade. Therefore, the immune impacts of H2R blockade may require greater consideration in the context of vaccination and immunotherapy.


Subject(s)
Histamine H2 Antagonists/adverse effects , Leukocytes/drug effects , Ranitidine/adverse effects , Adult , CD4 Lymphocyte Count , Female , Healthy Volunteers , Histamine H2 Antagonists/immunology , Humans , Immunomodulation , Interleukin-2/blood , Male , Middle Aged , Prospective Studies , Ranitidine/immunology , Young Adult
7.
Rev. mex. anestesiol ; 22(1): 31-5, ene.-mar. 1999. tab, graf
Article in Spanish | LILACS | ID: lil-276559

ABSTRACT

La permeabilidad vascular puede ser modificada por la liberación de histamina endógena como resultado de la presencia de ciertos tiobarbitúricos (tiopental) en el organismo. Esta modificación en la permeabilidad es mediada por la activación del receptor histaminérgico H1, pero es incierta la participación del receptor H2. En este trabajo se evalúa la participación de receptores H1 y H2 durante los cambios de permeabilidad vascular inducidos por histamina, a través de la determinación de concentraciones séricas de albúmina, proteínas totales y globulinas, que indirectamente lo indican. Se formaron 5 grupos de organismos; un control y 4 experimentales denominados grupo A, B, C y D. A los organismos del grupo A se les aplicó histamina IV, 10 µg/Kg de peso, y finalmente al grupo D se le inyectó simultáneamente 0.16 mg/Kg de peso; al grupo C se le inyectó ranitidina IV, 0.13 mg/Kg de peso, y finalmente al grupo D se le inyectó simultáneamente 0.16 mg/Kg de peso y 0.13 mg/Kg de peso de astemizol y ranitidina IV, respectivamente. El grupo A mostró un decremento significativo en las concentraciones de albúmina, proteínas totales y globulinas. En los grupos B, C y D se observó una disminución en la concentración de proteínas totales y globulinas, pero no de albúmina. Estos resultados muestran que los receptores H1 y H2 están involucrados en el aumento de permeabilidad vascular a la albúmina, pero tal vez exista un proceso de permeabilidad diferencial en el cual el paso de globulinas desde la luz vascular hasta el intersticio esté regulado por otro mecanismo


Subject(s)
Animals , Rats , Capillary Permeability/immunology , Receptors, Histamine H1/drug effects , Receptors, Histamine H2/drug effects , Ranitidine/immunology , Thiopental/immunology , Receptors, Histamine/drug effects , Astemizole/immunology , Albumins/immunology
8.
J Pharm Biomed Anal ; 19(5): 695-707, 1999 Apr.
Article in English | MEDLINE | ID: mdl-10698534

ABSTRACT

High affinity, specific murine monoclonal antibodies have been produced for ranitidine using the novel RIMMS (repetitive immunizations, multiple sites) technique. We demonstrate that this technique can be employed to produce high affinity monoclonal antibodies to drug haptens in approximately 1 month; whereas, conventional techniques typically require 3-9 months. Polyclonal antiserum development typically requires at least 6 months. Consequently, RIMMS has a clear impact allowing reagent antibodies to be available earlier in the drug development process. Isotyping studies demonstrated that the developed antibodies are either IgG1 or IgG2b immunoglobulins which confirms that the technique produces class-switched, affinity matured reagent antibodies. The most promising monoclonal antibody for quantitative applications afforded similar sensitivity, by competitive ELISA, to the established sheep polyclonal anti-ranitidine sera. The calibration range, estimated as the limits between the asymptotic regions of calibration graphs, is 0.5-41.2 ng ranitidine per well. Specificity studies indicated that the monoclonal antibody afforded superior selectivity, yielding only 4.1% cross-reactivity with the ranitidine sulphoxide metabolite; the corresponding value for the antiserum was 8.6%. Both reagents had similar cross-reactivities with the N-oxide metabolite.


Subject(s)
Antibodies, Monoclonal/biosynthesis , Immunization Schedule , Ranitidine/immunology , Animals , Calibration , Cell Fusion , Cells, Cultured , Enzyme-Linked Immunosorbent Assay , Flow Cytometry , Haptens/immunology , Hybridomas/immunology , Indicators and Reagents , Mice , Proteins/chemistry , Proteins/immunology , Radioimmunoassay , Ranitidine/chemistry , Solutions
9.
Masui ; 42(12): 1833-7, 1993 Dec.
Article in Japanese | MEDLINE | ID: mdl-8301834

ABSTRACT

We reported two cases of anaphylactoid reaction caused by ranitidine and alprostadil. We suggest that these anaphylactoid reactions are nonspecific reactions which are observed in low IgE patients, because plasma IgE was still low 6 weeks after allergic reaction and these drugs have not been given to them before and eosinophilic and basophilic cells showed no change at all. We have to consider that there is a high risk of allergic reaction during general anesthesia, because many drugs are injected intravenously during general anesthesia.


Subject(s)
Anaphylaxis/etiology , Dysgammaglobulinemia/complications , Immunoglobulin E/deficiency , Adult , Aged , Alprostadil/adverse effects , Alprostadil/immunology , Anesthesia, General , Dysgammaglobulinemia/immunology , Female , Humans , Ranitidine/adverse effects , Ranitidine/immunology
10.
Postepy Hig Med Dosw ; 47(5): 365-73, 1993.
Article in Polish | MEDLINE | ID: mdl-7909600

ABSTRACT

The clinical aspects and their possible implication in the several disease treatment have been reviewed in the context of the immunomodulatory H2-receptor antagonist action. The therapeutical possibility considering the perspectives of the application of the H2-receptor blockers has been discussed.


Subject(s)
Histamine H2 Antagonists/immunology , Animals , Cimetidine/immunology , Histamine H2 Antagonists/therapeutic use , Humans , Immune System/drug effects , Neoplasms, Experimental/drug therapy , Neoplasms, Experimental/immunology , Ranitidine/immunology , Reference Values
11.
Indian J Gastroenterol ; 9(1): 95-6, 1990 Jan.
Article in English | MEDLINE | ID: mdl-2307508

ABSTRACT

Candida albicans was found to repeatedly colonise and invade the duodenal ulcer base in a 45 years old otherwise healthy patient receiving H2 receptor antagonists for a prolonged period. He had no delayed hypersensitivity to Candida skin test, and had T cell deficiency, abnormality in T cell blast transformation, defective macrophage migration inhibition factor (MIF) and IgA hypogammaglobulinemia. When treated with ketoconazole alone his ulcer healed completely. Ulcer scar biopsy and aspirates revealed no Candida and anti candidal antibodies disappeared from his serum. His T cell blastoid transformation, MIF and skin DTH to Candida were restored to normal levels, but IgA levels remained unchanged. Thus H2 receptor antagonists probably caused abnormalities in T helper cells leading to lymphokine unresponsiveness and subsequently loss of cellular immunity to candidal antigen. This combined with prior IgA immunodeficiency resulted into severe invasive candidiasis.


Subject(s)
Candidiasis/immunology , Duodenal Ulcer/immunology , Dysgammaglobulinemia/complications , IgA Deficiency , Candidiasis/drug therapy , Cimetidine/immunology , Duodenal Ulcer/drug therapy , Humans , Immune Tolerance , Male , Middle Aged , Ranitidine/immunology , T-Lymphocytes/immunology
15.
Tokai J Exp Clin Med ; 8(4): 307-15, 1983 Nov.
Article in English | MEDLINE | ID: mdl-6149636

ABSTRACT

Antibodies against histamine H2-receptor antagonist "Famotidine (FAMO)", molecular weight 337, chemical name; N-sulfamoyl-3-(2-guanidinothiazol-4-ylmethylthio) propionamide, were produced by subcutaneously injecting rabbits with an albumin and FAMO conjugate covalently bound with 1-ethyl-3-(3-dimethyl-amino-propyl) carbodiimide (ECDI). Two new detection systems for antibody titration were developed and employed. In one method, the antigen FAMO was tagged to sheep red blood cells (SRBC) and analysed qualitatively by a fluorescence activated cell sorter (FACS) using a second fluorescence isothiocyanate (FITC) labeled antibody. In the other method, CH-Sepharose beads were employed in place of SRBC and Horse Radish Peroxidase (HRP) was labeled to the second antibody instead of FITC used in the former method. HRP of the immune complex was colorimetrically measured with DAB-H2O2 to analyse the fine antibody titer. These high sensitive detection methods revealed the existence of IgG type of FAMO antibody. The detection sensitive detection methods revealed the existence of IgG type of FAMO antibody. The detection sensitivity was approximately 50 to 100 times higher in the later method with HRP than in the former. Furthermore these two methods could be deemed to be a good model system for a receptor assay.


Subject(s)
Antibodies/analysis , Antibody Formation , Haptens/immunology , Histamine H2 Antagonists/immunology , Thiazoles/immunology , Animals , Antibody Specificity , Cimetidine/immunology , Famotidine , Fluorescent Antibody Technique , Molecular Weight , Rabbits , Ranitidine/immunology
SELECTION OF CITATIONS
SEARCH DETAIL
...